(Q40141892)

17 September 2017

Neuroendocrine effects of endogenous opioid peptides in human subjects: a review (English)

1 reference

17 September 2017

Neuroendocrine effects of endogenous opioid peptides in human subjects: A review (English)

1 reference

https://api.crossref.org/works/10.1016/0306-4530(83)90016-1

human subject research project

29 September 2023

main subject

0 references

1 reference

https://api.crossref.org/works/10.1016/0306-4530(83)90016-1

29 September 2023

author name string

J. E. Morley

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A6326175

29 September 2023

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=6326175

29 September 2023

publication date

1 January 1983

1 reference

full work available at URL

17 September 2017

https://api.elsevier.com/content/article/PII:0306453083900161?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/0306-4530(83)90016-1

https://api.elsevier.com/content/article/PII:0306453083900161?httpAccept=text/plain

29 September 2023

1 reference

https://api.crossref.org/works/10.1016/0306-4530(83)90016-1

29 September 2023

published in

Psychoneuroendocrinology

1 reference

17 September 2017

8

1 reference

17 September 2017

4

1 reference

17 September 2017

361-379

1 reference

Effects of a met-enkephalin analog on adrenocorticotropin (ACTH), growth hormone, and prolactin in patients with ACTH hypersecretion

17 September 2017

1

1 reference

https://api.crossref.org/works/10.1016/0306-4530(83)90016-1

Naloxone decreases food intake in obese humans

29 September 2023

2

1 reference

https://api.crossref.org/works/10.1016/0306-4530(83)90016-1

Endorphins and the regulations of the human menstrual cycle

29 September 2023

5

1 reference

https://api.crossref.org/works/10.1016/0306-4530(83)90016-1

Hyper-endorphin syndrome in a child with necrotizing encephalomyelopathy

29 September 2023

6

1 reference

https://api.crossref.org/works/10.1016/0306-4530(83)90016-1

Novel Opioid Peptides Derived from Casein (β-Casomorphins). I. Isolation from Bovine Casein Peptone

29 September 2023

7

1 reference

https://api.crossref.org/works/10.1016/0306-4530(83)90016-1

Inhibition of vasopressin secretion by a met-enkephalin (FK 33-824) in humans

29 September 2023

8

1 reference

https://api.crossref.org/works/10.1016/0306-4530(83)90016-1

Intravenous infusion of beta-endorphin increases serum prolactin, but not growth hormone or cortisol, in depressed subjects and withdrawing methadone addicts

29 September 2023

9

1 reference

https://api.crossref.org/works/10.1016/0306-4530(83)90016-1

Growth Hormone in Narcotic Addiction

29 September 2023

12

1 reference

https://api.crossref.org/works/10.1016/0306-4530(83)90016-1

Methadone induced hypoadrenalism

29 September 2023

13

1 reference

https://api.crossref.org/works/10.1016/0306-4530(83)90016-1

Prolactin-releasing activity of dermorphin, a new synthetic potent opiate-like peptide, in normal human subjects

29 September 2023

14

1 reference

https://api.crossref.org/works/10.1016/0306-4530(83)90016-1

Dopamine inhibits the naloxone induced gonadotrophin rise in man

29 September 2023

15

1 reference

https://api.crossref.org/works/10.1016/0306-4530(83)90016-1

Effects of a Met-Enkephalin Analogue and Naloxone Infusion on Anterior Pituitary Hormone Secretion in Acromegaly

29 September 2023

17

1 reference

https://api.crossref.org/works/10.1016/0306-4530(83)90016-1

Effect of a met-enkephalin analogue and naloxone infusion on gonadotrophin secretion in man

29 September 2023

18

1 reference

https://api.crossref.org/works/10.1016/0306-4530(83)90016-1

Changes in pituitary hormone levels induced by met-enkephalin in man--the role of dopamine

29 September 2023

20

1 reference

https://api.crossref.org/works/10.1016/0306-4530(83)90016-1

Opiate peptides control growth hormone through a cholinergic mechanism in man

29 September 2023

22

1 reference

https://api.crossref.org/works/10.1016/0306-4530(83)90016-1

Inhibitory action of a met-enkephalin on ACTH release in man

29 September 2023

23

1 reference

https://api.crossref.org/works/10.1016/0306-4530(83)90016-1

Endocrine Effect of a Methionine-Enkephalin Derivative (FK 33-824) in Man

29 September 2023

24

1 reference

https://api.crossref.org/works/10.1016/0306-4530(83)90016-1

Plasma pituitary hormone responses to the synthetic enkephalin analog (FK 33-824) in normal subjects and patients with pituitary diseases

29 September 2023

25

1 reference

https://api.crossref.org/works/10.1016/0306-4530(83)90016-1

Plasma LH, FSH and TSH responses to the synthetic enkephalin analog (FK 33-824) in normal subjects and patients with pituitary diseases

29 September 2023

26

1 reference

https://api.crossref.org/works/10.1016/0306-4530(83)90016-1

Diurnal rhythm of plasma immunoreactive beta-endorphin and its relationship to sleep stages and plasma rhythms of cortisol and prolactin

29 September 2023

27

1 reference

https://api.crossref.org/works/10.1016/0306-4530(83)90016-1

Opiate Receptors Modulate LHRH and SRIF Release from Mediobasal Hypothalamic Neurons

29 September 2023

29

1 reference

https://api.crossref.org/works/10.1016/0306-4530(83)90016-1

Effect of naloxone in a previously undescribed hypothalamic syndrome. A disorder of the endogenous opioid peptide system?

29 September 2023

30

1 reference

https://api.crossref.org/works/10.1016/0306-4530(83)90016-1

Effects of valproic acid, naloxone and hydrocortisone in Nelson's syndrome and cushing's disease

29 September 2023

31

1 reference

https://api.crossref.org/works/10.1016/0306-4530(83)90016-1

Effects of heroin and naltrexone on plasma prolactin levels in man.

29 September 2023

32

1 reference

https://api.crossref.org/works/10.1016/0306-4530(83)90016-1

Effect of endogenous opioid blockade on the amplitude and frequency of pulsatile luteinizing hormone secretion in normal men.

29 September 2023

33

1 reference

https://api.crossref.org/works/10.1016/0306-4530(83)90016-1

The hyperglycaemic effect of morphine

29 September 2023

34

1 reference

https://api.crossref.org/works/10.1016/0306-4530(83)90016-1

Beta-endorphin and the endocrine pancreas. Studies in healthy and diabetic human beings.

29 September 2023

35

1 reference

https://api.crossref.org/works/10.1016/0306-4530(83)90016-1

The effects of a met-enkephalin analogue on ACTH, beta-LPH, beta-endorphin and MET-enkephalin in patients with adrenocortical disease

29 September 2023

37

1 reference

https://api.crossref.org/works/10.1016/0306-4530(83)90016-1

Morphine Anesthesia Blocks Cortisol and Growth Hormone Response to Surgical Stress in Humans

29 September 2023

38

1 reference

https://api.crossref.org/works/10.1016/0306-4530(83)90016-1

beta-Endorphin enhances lymphocyte proliferative responses

29 September 2023

39

1 reference

https://api.crossref.org/works/10.1016/0306-4530(83)90016-1

Impaired Insulin Secretion in Human Diabetes Mellitus: The Effect of Naloxone-Induced Opiate Receptor Blockade

29 September 2023

40

1 reference

https://api.crossref.org/works/10.1016/0306-4530(83)90016-1

Evidence for an endorphin dysfunction in methadone addicts: Lack of ACTH response to naloxone

29 September 2023

41

1 reference

https://api.crossref.org/works/10.1016/0306-4530(83)90016-1

A Case of Episodic Flushing and Organic Psychosis: Reversal by Opiate Antagonists

29 September 2023

42

1 reference

https://api.crossref.org/works/10.1016/0306-4530(83)90016-1

Inhibition of vasopressin release in man by an opiate peptide

29 September 2023

44

1 reference

https://api.crossref.org/works/10.1016/0306-4530(83)90016-1

The opioid control of LH and FSH release: effects of a met-enkephalin analogue and naloxone

29 September 2023

45

1 reference

https://api.crossref.org/works/10.1016/0306-4530(83)90016-1

Studies off the opiate control of prolactin, GH and TSH

29 September 2023

46

1 reference

https://api.crossref.org/works/10.1016/0306-4530(83)90016-1

Opiates control ACTH through a noradrenergic mechanism

29 September 2023

47

1 reference

https://api.crossref.org/works/10.1016/0306-4530(83)90016-1

Opiate modulation of the pituitary-adrenal axis: effects of stress and circadian rhythm

29 September 2023

48

1 reference

https://api.crossref.org/works/10.1016/0306-4530(83)90016-1

Opiate mediation of amenorrhoea in hyperprolactinaemia and in weight-loss related amenorrhoea

29 September 2023

49

1 reference

https://api.crossref.org/works/10.1016/0306-4530(83)90016-1

The role of opiate peptides in the control of prolactin in the puerperium, and TSH in primary hypothyroidism

29 September 2023

50

1 reference

https://api.crossref.org/works/10.1016/0306-4530(83)90016-1

The neuroendocrinology of opioid peptides

29 September 2023

51

1 reference

https://api.crossref.org/works/10.1016/0306-4530(83)90016-1

Specific Nonopiate Receptors for β-Endorphin

29 September 2023

52

1 reference

https://api.crossref.org/works/10.1016/0306-4530(83)90016-1

Natural killer cells: characteristics and regulation of activity

29 September 2023

53

1 reference

https://api.crossref.org/works/10.1016/0306-4530(83)90016-1

Opioid Peptides: introduction

29 September 2023

54

1 reference

https://api.crossref.org/works/10.1016/0306-4530(83)90016-1

Effects of naloxone-HCl on cortisol levels in patients with affective disorder and normal controls

29 September 2023

56

1 reference

https://api.crossref.org/works/10.1016/0306-4530(83)90016-1

Blunted prolactin response. A neuroendocrine abnormality manifested by depressed patients

29 September 2023

57

1 reference

https://api.crossref.org/works/10.1016/0306-4530(83)90016-1

Endogenous opioid mechanism in neuroendocrine regulation in normal and psychopathological states

29 September 2023

58

1 reference

https://api.crossref.org/works/10.1016/0306-4530(83)90016-1

Cerebrospinal fluid opioid activity in anorexia nervosa

29 September 2023

60

1 reference

https://api.crossref.org/works/10.1016/0306-4530(83)90016-1

Naloxone in chronic schizophrenic patients: neuroendocrine and behavioral effects

29 September 2023

61

1 reference

https://api.crossref.org/works/10.1016/0306-4530(83)90016-1

Effect of naloxone on hyperphagia in Prader-Willi syndrome

29 September 2023

62

1 reference

https://api.crossref.org/works/10.1016/0306-4530(83)90016-1

A Met-Enkephalin Analog Inhibits Adrenocorticotropin Secretion by Cultured Pituitary Cells from a Patient with Nelson's Syndrome*

29 September 2023

63

1 reference

https://api.crossref.org/works/10.1016/0306-4530(83)90016-1

The effect of long-term naloxone infusion on the response of gonadotropins to luteinizing hormone-releasing hormone and on plasma estradiol concentration in a patient with a prolactin-secreting pituitary adenoma

29 September 2023

64

1 reference

https://api.crossref.org/works/10.1016/0306-4530(83)90016-1

Failure of naloxone to antagonize metoclopramide induced prolactin rise

29 September 2023

65

1 reference

https://api.crossref.org/works/10.1016/0306-4530(83)90016-1

Chlorpropamide-alcohol flushing: a dominantly inherited trait associated with diabetes

29 September 2023

66

1 reference

https://api.crossref.org/works/10.1016/0306-4530(83)90016-1

Sensitivity to enkephalin as a cause of non-insulin dependent diabetes

29 September 2023

67

1 reference

https://api.crossref.org/works/10.1016/0306-4530(83)90016-1

Opiate receptors and the metabolic response to intravenous glucose

29 September 2023

68

1 reference

https://api.crossref.org/works/10.1016/0306-4530(83)90016-1

Evidence for endogenous opioid control of vasopressin release in man.

29 September 2023

69

1 reference

https://api.crossref.org/works/10.1016/0306-4530(83)90016-1

Effects of the opiate antagonist naloxone and the enkephalin analog DAMME on the vasopressin response to a hypertonic stimulus in man

29 September 2023

70

1 reference

https://api.crossref.org/works/10.1016/0306-4530(83)90016-1

Climacteric flushing: clinical and endocrine response to infusion of naloxone

29 September 2023

71

1 reference

https://api.crossref.org/works/10.1016/0306-4530(83)90016-1

Constancy of opioid control of luteinizing hormone in different pathophysiological states

29 September 2023

72

1 reference

https://api.crossref.org/works/10.1016/0306-4530(83)90016-1

Naloxone increases the nicotine-stimulated rise of vasopressin secretion in man

29 September 2023

73

1 reference

https://api.crossref.org/works/10.1016/0306-4530(83)90016-1

Stereoselective muscarinic acetylcholine and opiate receptors in human phagocytic leukocytes

29 September 2023

74

1 reference

https://api.crossref.org/works/10.1016/0306-4530(83)90016-1

Failure of naloxone to influence physiological growth hormone and prolactin secretion

29 September 2023

75

1 reference

https://api.crossref.org/works/10.1016/0306-4530(83)90016-1

Endogenous opiates modulate insulin secretion in flushing noninsulin-dependent diabetics

29 September 2023

76

1 reference

https://api.crossref.org/works/10.1016/0306-4530(83)90016-1

Failure of naloxone to alter exercise-induced growth hormone and prolactin release in normal men

29 September 2023

77

1 reference

https://api.crossref.org/works/10.1016/0306-4530(83)90016-1

Effect of morphine and nalorphine on plasma hydrocortisone levels in man

29 September 2023

78

1 reference

https://api.crossref.org/works/10.1016/0306-4530(83)90016-1

Chlorpropamide alcohol flush and circulating met-enkephalin: a positive link

29 September 2023

79

1 reference

https://api.crossref.org/works/10.1016/0306-4530(83)90016-1

Heroin and naltrexone effects on pituitary-gonadal hormones in man: interaction of steroid feedback effects, tolerance and supersensitivity

29 September 2023

80

1 reference

https://api.crossref.org/works/10.1016/0306-4530(83)90016-1

Role of Endogenous Opioids in Neurohypophysial Function of Man*

29 September 2023

81

1 reference

https://api.crossref.org/works/10.1016/0306-4530(83)90016-1

Naloxone in the treatment of anorexia nervosa: effect on weight gain and lipolysis

29 September 2023

82

1 reference

https://api.crossref.org/works/10.1016/0306-4530(83)90016-1

Naloxone inhibits exercise-induced release of PRL and GH in athletes

29 September 2023

83

1 reference

https://api.crossref.org/works/10.1016/0306-4530(83)90016-1

The neuroendocrine control of appetite: the role of the endogenous opiates, cholecystokinin, TRH, gamma-amino-butyric-acid and the diazepam receptor

29 September 2023

84

1 reference

https://api.crossref.org/works/10.1016/0306-4530(83)90016-1

The endocrinology of the opiates and opioid peptides

29 September 2023

85

1 reference

https://api.crossref.org/works/10.1016/0306-4530(83)90016-1

Neuroendocrine control of thyrotropin secretion

29 September 2023

86

1 reference

https://api.crossref.org/works/10.1016/0306-4530(83)90016-1

Gonadal dysfunction in systemic disorders

29 September 2023

89

1 reference

https://api.crossref.org/works/10.1016/0306-4530(83)90016-1

Stress-Induced Eating Is Mediated Through Endogenous Opiates

29 September 2023

90

1 reference

https://api.crossref.org/works/10.1016/0306-4530(83)90016-1

Dynorphin-(1–13) induces spontaneous feeding in rats

29 September 2023

91

1 reference

https://api.crossref.org/works/10.1016/0306-4530(83)90016-1

The role of the endogenous opiates as regulators of appetite

29 September 2023

92

1 reference

https://api.crossref.org/works/10.1016/0306-4530(83)90016-1

The central control of appetite

29 September 2023

93

1 reference

https://api.crossref.org/works/10.1016/0306-4530(83)90016-1

Endocrine Effects of Naloxone-Induced Opiate Receptor Blockade *

29 September 2023

94

1 reference

https://api.crossref.org/works/10.1016/0306-4530(83)90016-1

Morphine addiction and withdrawal alters brain peptide concentrations.

29 September 2023

95

1 reference

https://api.crossref.org/works/10.1016/0306-4530(83)90016-1

Dynorphin-(1–13), dopamine and feeding in rats

29 September 2023

96

1 reference

https://api.crossref.org/works/10.1016/0306-4530(83)90016-1

Neuropeptides and thermoregulation: the interactions of bombesin, neurotensin, TRH, somatostatin, naloxone and prostaglandins

29 September 2023

97

1 reference

https://api.crossref.org/works/10.1016/0306-4530(83)90016-1

Opioid modulation of appetite

29 September 2023

98

1 reference

https://api.crossref.org/works/10.1016/0306-4530(83)90016-1

The effect of naloxone on pulsatile gonadotrophin release in normal subjects

29 September 2023

100

1 reference

https://api.crossref.org/works/10.1016/0306-4530(83)90016-1

Diuretic action of the narcotic antagonist oxilorphan

29 September 2023

101

1 reference

https://api.crossref.org/works/10.1016/0306-4530(83)90016-1

Mechanisms of insulin resistance in obesity and noninsulin-dependent (type II) diabetes.

29 September 2023

102

1 reference

https://api.crossref.org/works/10.1016/0306-4530(83)90016-1

Effect of exogenous β-endorphin on anterior pituitary hormone secretion in man

29 September 2023

103

1 reference

https://api.crossref.org/works/10.1016/0306-4530(83)90016-1

Effects of naloxone on prolactin, luteinizing hormone, and cortisol responses to surgical stress in humans.

29 September 2023

104

1 reference

https://api.crossref.org/works/10.1016/0306-4530(83)90016-1

Methadone-induced hypoadrenalism

29 September 2023

105

1 reference

https://api.crossref.org/works/10.1016/0306-4530(83)90016-1

The role of endogenous opiates in LH secretion during the menstrual cycle

29 September 2023

106

1 reference

https://api.crossref.org/works/10.1016/0306-4530(83)90016-1

Evidence for an increased opioid inhibition of luteinizing hormone secretion in hyperprolactinemic patients with pituitary microadenoma

29 September 2023

107

1 reference

https://api.crossref.org/works/10.1016/0306-4530(83)90016-1

Evidence for Increased Dopaminergic and Opioid Activity in Patients with Hypothalamic Hypogonadotropic Amenorrhea*

29 September 2023

108

1 reference

https://api.crossref.org/works/10.1016/0306-4530(83)90016-1

Met-enkephalin inhibits mineralocorticoid production in isolated human aldosteronoma cells

29 September 2023

109

1 reference

https://api.crossref.org/works/10.1016/0306-4530(83)90016-1

beta-Endorphin stimulates the secretion of insulin and glucagon in humans.

29 September 2023

110

1 reference

https://api.crossref.org/works/10.1016/0306-4530(83)90016-1

The effect of beta-endorphin on arginine-induced growth hormone and prolactin release

29 September 2023

111

1 reference

https://api.crossref.org/works/10.1016/0306-4530(83)90016-1

Effects of Exogenous βh-Endorphin on Pituitary Hormone Secretionand Its Disappearance Rate in Normal Human Subjects*

29 September 2023

112

1 reference

https://api.crossref.org/works/10.1016/0306-4530(83)90016-1

Endogenous opiates modulate pulsatile luteinizing hormone release in humans

29 September 2023

114

1 reference

https://api.crossref.org/works/10.1016/0306-4530(83)90016-1

Met-enkephalin inhibits in vitro dopamine-induced LHRH release from mediobasal hypothalamus of male rats

29 September 2023

115

1 reference

https://api.crossref.org/works/10.1016/0306-4530(83)90016-1

Naloxone lowers plasma-prolactin in man.

29 September 2023

116

1 reference

https://api.crossref.org/works/10.1016/0306-4530(83)90016-1

Enhanced Frequency and Magnitude of Episodic Luteinizing Hormone-Releasing Hormone Discharge as a Hypothalamic Mechanism for Increased Luteinizing Hormone Secretion*

29 September 2023

117

1 reference

https://api.crossref.org/works/10.1016/0306-4530(83)90016-1

Prolactin response to beta-endorphin in man

29 September 2023

118

1 reference

https://api.crossref.org/works/10.1016/0306-4530(83)90016-1

Evidence for an effect of exorphins on plasma insulin and glucagon levels in dogs

29 September 2023

119

1 reference

https://api.crossref.org/works/10.1016/0306-4530(83)90016-1

Effects of Naloxone on Insulin-Induced Release of Pituitary Hormones

29 September 2023

120

1 reference

https://api.crossref.org/works/10.1016/0306-4530(83)90016-1

The role of opiates and endogenous opioid peptides in the regulation of rat TSH secretion

29 September 2023

121

1 reference

https://api.crossref.org/works/10.1016/0306-4530(83)90016-1

Effects of Chronic Methadone Administration on the Hypothalamic-Pituitary-Thyroid Axis

29 September 2023

122

1 reference

https://api.crossref.org/works/10.1016/0306-4530(83)90016-1

Human lymphocyte production of corticotropin and endorphin-like substances: association with leukocyte interferon

29 September 2023

123

1 reference

https://api.crossref.org/works/10.1016/0306-4530(83)90016-1

Immunity, emotions and stress with special reference to the mechanisms of stress effects on the immune system.

29 September 2023

124

1 reference

https://api.crossref.org/works/10.1016/0306-4530(83)90016-1

Lack of Modulation of Pituitary Hormone Stress Response by Neural Pathways Involving Opiate Receptors*

29 September 2023

125

1 reference

https://api.crossref.org/works/10.1016/0306-4530(83)90016-1

Naloxone-induced decrease of plasma prolactin in healthy women

29 September 2023

126

1 reference

https://api.crossref.org/works/10.1016/0306-4530(83)90016-1

Anorexic effects of naltrexone in man.

29 September 2023

127

1 reference

https://api.crossref.org/works/10.1016/0306-4530(83)90016-1

Influence of Brain and Behavior on the Immune System

29 September 2023

128

1 reference

https://api.crossref.org/works/10.1016/0306-4530(83)90016-1

Hormonal and metabolic responses to an enkephalin analogue in normal man

29 September 2023

129

1 reference

https://api.crossref.org/works/10.1016/0306-4530(83)90016-1

Endogenous opioid poisoning?

29 September 2023

130

1 reference

https://api.crossref.org/works/10.1016/0306-4530(83)90016-1

Opiate receptor blockade in man reduces 2-deoxy-d-glucose-induced food intake but not hunger, thirst, and hypothermia

29 September 2023

132

1 reference

https://api.crossref.org/works/10.1016/0306-4530(83)90016-1

Effects of morphine on serum growth hormone, cortisol, prolactin and thyroid stimulating hormone in man

29 September 2023

133

1 reference

https://api.crossref.org/works/10.1016/0306-4530(83)90016-1

Effect of Naloxone on Pituitary Hypersecretory Syndromes*

29 September 2023

134

1 reference

https://api.crossref.org/works/10.1016/0306-4530(83)90016-1

A possible role for endogenous opioids in the control of prolactin and luteinizing-hormone secretion in the human

29 September 2023

135

1 reference

https://api.crossref.org/works/10.1016/0306-4530(83)90016-1

Responsiveness of gonadotropin secretion to infusion of an opiate-receptor antagonist in hypogonadotropic individuals

29 September 2023

136

1 reference

https://api.crossref.org/works/10.1016/0306-4530(83)90016-1

Short-term hormonal effects of naloxone in man

29 September 2023

137

1 reference

https://api.crossref.org/works/10.1016/0306-4530(83)90016-1

Failure of naloxone to influence plasma growth hormone, prolactin, and cortisol secretions induced by insulin hypoglycemia

29 September 2023

138

1 reference

https://api.crossref.org/works/10.1016/0306-4530(83)90016-1

Suggestive evidence for receptors for morphine and methionine-enkephalin on normal human blood T lymphocytes

29 September 2023

139

1 reference

https://api.crossref.org/works/10.1016/0306-4530(83)90016-1

Naloxone and anterior pituitary hormones: effect on TRH stimulation test

29 September 2023

140

1 reference

https://api.crossref.org/works/10.1016/0306-4530(83)90016-1

A new Met-enkephalin analogue suppresses plasma vasopressin in man

29 September 2023

141

1 reference

https://api.crossref.org/works/10.1016/0306-4530(83)90016-1

29 September 2023

Identifiers

1 reference

17 September 2017

1 reference